Martin Riediker

Perseo pharma AG is a Swiss preclinical stage biopharmaceutical company that focuses on discovering and developing enzyme therapeutics for the treatment of digestive diseases. The company is based in Muttenz, Switzerland. The company has entered into a strategic research and development collaboration with Nestlé Health Science to develop novel therapies for digestive diseases. Perseo pharma's innovative technology is based on therapeutic enzymes that are protected in a nano shield with muco-adhesive coating. The company is a spin-off from the University of Applied Sciences (FHNW), School of Life Sciences in Switzerland, and was founded by Prof. Dr. Patrick Shahgaldian. Yves Dudal has been the CEO of the company since 2019.

INOFEA AG is a Swiss biotech company founded in 2014 that works closely with its clients to provide them with a complex line of services that sustain their processes and products. The company is based in Muttenz, Switzerland. The company has developed a patented platform technology called enzzen® that empowers enzymes to fit industrial applications. Enzymes are protein molecules that carry a vital energy factor needed for every chemical reaction and reactions that occur in any living organism. INOFEA has successfully demonstrated the added-value of their technology for enzyme-mediated bioconjugation or post-translational modifications of antibodies or other large molecules. Anne Timm has been the CEO of the company since 2018.

Perseo pharma AG is a Swiss preclinical stage biopharmaceutical company that focuses on discovering and developing enzyme therapeutics for the treatment of digestive diseases. The company is based in Muttenz, Switzerland. The company has entered into a strategic research and development collaboration with Nestlé Health Science to develop novel therapies for digestive diseases. Perseo pharma's innovative technology is based on therapeutic enzymes that are protected in a nano shield with muco-adhesive coating. The company is a spin-off from the University of Applied Sciences (FHNW), School of Life Sciences in Switzerland, and was founded by Prof. Dr. Patrick Shahgaldian. Yves Dudal has been the CEO of the company since 2019.

INOFEA AG is a Swiss biotech company founded in 2014 that works closely with its clients to provide them with a complex line of services that sustain their processes and products. The company is based in Muttenz, Switzerland. The company has developed a patented platform technology called enzzen® that empowers enzymes to fit industrial applications. Enzymes are protein molecules that carry a vital energy factor needed for every chemical reaction and reactions that occur in any living organism. INOFEA has successfully demonstrated the added-value of their technology for enzyme-mediated bioconjugation or post-translational modifications of antibodies or other large molecules. Anne Timm has been the CEO of the company since 2018.

Diality, Inc. is engaged in manufacturing medical devices. The company is headquartered in Irvine, CA.

Perseo pharma AG is a Swiss preclinical stage biopharmaceutical company that focuses on discovering and developing enzyme therapeutics for the treatment of digestive diseases. The company is based in Muttenz, Switzerland. The company has entered into a strategic research and development collaboration with Nestlé Health Science to develop novel therapies for digestive diseases. Perseo pharma's innovative technology is based on therapeutic enzymes that are protected in a nano shield with muco-adhesive coating. The company is a spin-off from the University of Applied Sciences (FHNW), School of Life Sciences in Switzerland, and was founded by Prof. Dr. Patrick Shahgaldian. Yves Dudal has been the CEO of the company since 2019.

INOFEA AG is a Swiss biotech company founded in 2014 that works closely with its clients to provide them with a complex line of services that sustain their processes and products. The company is based in Muttenz, Switzerland. The company has developed a patented platform technology called enzzen® that empowers enzymes to fit industrial applications. Enzymes are protein molecules that carry a vital energy factor needed for every chemical reaction and reactions that occur in any living organism. INOFEA has successfully demonstrated the added-value of their technology for enzyme-mediated bioconjugation or post-translational modifications of antibodies or other large molecules. Anne Timm has been the CEO of the company since 2018.

Perseo pharma AG is a Swiss preclinical stage biopharmaceutical company that focuses on discovering and developing enzyme therapeutics for the treatment of digestive diseases. The company is based in Muttenz, Switzerland. The company has entered into a strategic research and development collaboration with Nestlé Health Science to develop novel therapies for digestive diseases. Perseo pharma's innovative technology is based on therapeutic enzymes that are protected in a nano shield with muco-adhesive coating. The company is a spin-off from the University of Applied Sciences (FHNW), School of Life Sciences in Switzerland, and was founded by Prof. Dr. Patrick Shahgaldian. Yves Dudal has been the CEO of the company since 2019.